(via TheNewswire)
Through the MPA, BNA aims to expand its product range by introducing several new products that are derived from pea starch. Pea starch, considered the least valuable byproduct in pea protein production, will be transformed to create innovative and nutritious ingredients. This strategic initiative not only enhances the value of pea starch but also contributes to the overall stability of the plant protein industry.
Dr.
Additionally, BNA will investigate the requirements to build a large-scale production facility in
About BioNeutra
BioNeutra is an award-winning, sector-leading Canadian company in the business of research and development, production, and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages with a focus on its lead product - VitaFiber® IMO.
VitaFiber® IMO is made using a patented process that naturally transforms starch molecules from agricultural crops such as pea or tapioca into healthy, functional molecules. The VitaFiber manufacturing process is based upon a natural enzymatic conversion of the molecules without any chemical modification involved making VitaFiber® IMO a natural food and beverage ingredient. VitaFiber® IMO is also non-GMO, vegan friendly, gluten-free, Kosher and Halal certified and available as certified organic.
VitaFiber® IMO has been approved for sale by the world’s top three health regulatory bodies – GRAS approved by the
The Company’s customers include a mix of small and medium businesses as well as a number of high-profile food and beverage manufacturers on four continents.
Further information about BioNeutra is available on the Company’s website atwww.bioneutra.caand the SEDAR website atwww.sedarplus.ca.
Neither the
For further information on BioNeutra, please contact:
Dr.
President and Chief Executive Officer
Tel: (780) 466-1481 (Ext. 132)
Email:jianhua.zhu@bioneutra.ca
Forward-Looking Information
This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source